FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical ...
This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...
Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...
A key gene that fuels the molecular cascade driving prostate cancer bone metastasis progression may open avenues for targeted therapies. With this mda-9 mice model, Fisher and his team observed how ...
JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.
The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy (SBRT) with androgen receptor pathway inhibitors (ARPIs) in ...
Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate Traditionally, prostate cancer treatment, as well as all cancer treatment, has been designed to target the ...
Health-related quality of life after IMRT or IMRT+ HDR brachytherapy for intermediate or high-risk prostate cancer: Five-year results of a prospective trial. This is an ASCO Meeting Abstract from the ...
In May 2025, former President Joe Biden's health took a serious turn when his medical team revealed a diagnosis of aggressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback